NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
edesabiotech.comEDSA expects the completion of its clinical trial for paridiprubart, a potential treatment for acute respiratory distress syndrome (ARDS), on February 8, 2028. The trial, sponsored by PPD Development, LP, is part of a Phase 2 master protocol evaluating host-directed therapeutic candidates for ARDS. With a current enrollment target of 200 participants, the study will assess safety and efficacy through various clinical measures over a 90-day period following treatment. Participants will continue to receive standard ARDS treatments alongside the investigational product or placebo. As of now, the trial status is recruiting.
Clinical Trial Expected Completion DateThe Bevacizumab cohort of the JUST BREATHE clinical trial, designed to evaluate investigational therapies for Acute Respiratory Distress Syndrome (ARDS), is expected to complete on February 8, 2028. Sponsored by PPD Development, LP, the Phase 2 trial aims to assess the safety and efficacy of Bevacizumab against placebo in 200 hospitalized ARDS patients. Participants will be monitored for ventilatory status, oxygenation, survival, and functional status over a 90-day period post-treatment. As of now, the trial is still recruiting participants, which indicates ongoing interest and potential financial implications for EDSA, the related company listed in this study.
Clinical Trial CompletionEDSA is planning the completion of its Phase 2 clinical trial for acute respiratory distress syndrome (ARDS) on February 8, 2028. The trial, sponsored by PPD Development, LP, aims to evaluate various host-directed therapeutic candidates for ARDS treatment among hospitalized patients. Each investigational product will be tested against a placebo within individual patient cohorts. The study seeks to gather outcome data, including ventilatory status and survival rates, from approximately 600 enrolled participants over a roughly 90-day period. The trial is currently in the recruiting phase, having started on February 13, 2025. Key interim findings could influence future treatment strategies for ARDS and present significant market implications for the involved therapies.
Clinical Trial CompletionEDSA is anticipating the completion of its clinical trial for Vilobelimab, a therapeutic candidate for the treatment of Acute Respiratory Distress Syndrome (ARDS), by February 8, 2028. This trial, sponsored by PPD Development, LP, is part of a Phase 2 study evaluating the safety and efficacy of host-directed therapies for hospitalized patients with ARDS. The study aims to enroll 200 participants, with outcomes focusing on ventilatory status, oxygenation, survival, and healthcare resource utilization. As of now, the trial is in the recruiting phase, with an expected participant treatment duration of approximately 90 days. Detailed exploratory biomarker assessments will also be conducted to enhance clinical understanding. This information is integral to investors assessing the potential market impact of Vilobelimab.
Clinical Trial Completion